Skip to main content

InvestorNewsBreaks – DarioHealth Corp. (NASDAQ: DRIO) Plans to Release Q2 2024 Financial Results, Schedules Earnings Conference Call

DarioHealth (NASDAQ: DRIO), a leader in the global digital health market, is planning to release its financial results for the second quarter 2024, covering the period ended June 30, 2024. According to the announcement, the company will release the report on Aug. 8, 2024, before the market opens. In addition, the company has scheduled a conference call and webcast to discuss the financial results and business report; the call is slated to begin at 8:30 a.m. ET on the same day. DarioHealth CEO Erez Raphael and COO Steven Nelson will host the call. Those interested in accessing the call can dial 1-800-717-1738 (domestic) or 1-646-307-1865 (international). The company also noted that a recorded version of the call would be available. Those interested in listening to the recorded call can dial 1-844-512-2921 (domestic) or 1-412-317-6671 (international) and use passcode 1163410.

To access the event via Call Me(TM), visit https://ibn.fm/JU5Iz

To access the webcast, register at https://ibn.fm/0MKMo

To view the full press release, visit https://ibn.fm/0clwQ

About DarioHealth Corp.

DarioHealth Corp. is a leading digital health company revolutionizing how people with chronic conditions manage their health through a user-centric, multichronic-condition platform. Dario’s platform and suite of solutions deliver personalized and dynamic interventions driven by data analytics and one-on-one coaching for diabetes, hypertension, weight management, musculoskeletal pain and behavioral health. The company’s user-centric platform offers people continuous and customized care for their health, disrupting the traditional episodic approach to healthcare. This approach empowers people to holistically adapt their lifestyles for sustainable behavior change, driving exceptional user satisfaction, retention and results, and making the right thing to do the easy thing to do. Dario provides its highly user-rated solutions globally to health plans and other payors, self-insured employers and providers of care as well as directly to consumers. For more information about the company, please visit www.DarioHealth.com.

NOTE TO INVESTORS: The latest news and updates relating to DRIO are available in the company’s newsroom at http://ibn.fm/DRIO

About InvestorWire

InvestorWire (“IW”) is a specialized communications platform with a focus on advanced wire-grade press release syndication for private and public companies and the investment community. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, IW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, IW brings its clients unparalleled recognition and brand awareness. IW is where breaking news, insightful content and actionable information converge.

For more information, please visit https://www.InvestorWire.com

Please see full terms of use and disclaimers on the InvestorWire website applicable to all content provided by IW, wherever published or re-published: https://www.InvestorWire.com/Disclaimer

InvestorWire
Los Angeles, CA
www.InvestorWire.com
310.299.1717 Office
Editor@InvestorWire.com

InvestorWire is powered by IBN

Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.